# UCDCC#271: Phase I/II Trial of Epacadostat, Intralesional SD101, Radiotherapy in Patients With Lymphoma

> **NCT03322384** · PHASE1,PHASE2 · COMPLETED · sponsor: **University of California, Davis** · enrollment: 20 (actual)

## Conditions studied

- Advanced Solid Tumors
- Lymphoma

## Interventions

- **DRUG:** epacadostat
- **DRUG:** SD-101
- **RADIATION:** Radiotherapy

## Key facts

- **NCT ID:** NCT03322384
- **Lead sponsor:** University of California, Davis
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-17
- **Primary completion:** 2020-02-24
- **Final completion:** 2020-04-08
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2022-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03322384

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03322384, "UCDCC#271: Phase I/II Trial of Epacadostat, Intralesional SD101, Radiotherapy in Patients With Lymphoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03322384. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*